Cargando…
Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a new class of drugs that might have a potential beneficial effect on bone metabolism. Data on the effect of GLP-1 RAs and fracture risk are lacking. The aim of the present study was to investigate the association between the use of GLP-1 and...
Autores principales: | Driessen, Johanna H. M., van Onzenoort, Hein A. W., Starup-Linde, Jakob, Henry, Ronald, Burden, Andrea M., Neef, Cees, van den Bergh, Joop P., Vestergaard, Peter, de Vries, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598352/ https://www.ncbi.nlm.nih.gov/pubmed/26184119 http://dx.doi.org/10.1007/s00223-015-0037-y |
Ejemplares similares
-
Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis
por: Driessen, Johanna H. M., et al.
Publicado: (2015) -
The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study
por: Werkman, Nikki C. C., et al.
Publicado: (2023) -
RETRACTED ARTICLE: Secular trends in major osteoporotic fractures among 50+ adults in Denmark between 1995 and 2010
por: Abtahi, Shahab, et al.
Publicado: (2018) -
Secular trends in major osteoporotic fractures among 50+ adults in Denmark between 1995 and 2010
por: Abtahi, Shahab, et al.
Publicado: (2019) -
The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis
por: Safipour, Zohreh, et al.
Publicado: (2021)